Birch pollen allergy vaccine tablet - ALK-Abello
Alternative Names: Betula Verrucosa allergen extract; ITULAZAX; Oralgen Birch Pollen; SLIT birch pollen extract; SLITone Birch; SLITonePLUS Birch; SQ tree SLIT-tabletLatest Information Update: 10 Mar 2025
At a glance
- Originator ALK-Abello
- Class Allergens; Peptide vaccines; Peptides; Skin disorder therapies; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Allergic rhinoconjunctivitis
- Preregistration Allergic conjunctivitis; Allergic rhinitis
Most Recent Events
- 27 Feb 2025 ALK-Abello expects approval of the birch pollen vaccine tablet (In children, In adolescents) in Europe and Canada (Sublingual, Tablet), in 2025
- 30 Jan 2025 ALK plans to submit an application for a NICE review for ITULAZAX® (Birch pollen allergy vaccine tablet)
- 30 Jan 2025 ALK plans to submit an application for a NICE review to extend the approvals for ITULAZAX® (Birch pollen allergy vaccine tablet) to include children